Burgeoning demand for antiplatelet drugs to drive growth opportunities in the ticagrelor market
Ticagrelor Market |
The
ticagrelor market is estimated to be valued at US$ 1,578.2 million in 2023 and is expected to exhibit a CAGR of 12.3% over the forecast period 2023-2030, as highlighted in a
new report published by Coherent Market Insights.
Market Overview:
Ticagrelor is an antiplatelet drug used to prevent heart attacks and strokes in
patients with acute coronary syndrome or a history of myocardial infarction. It
works by inhibiting platelet activation and aggregation to prevent clots from
forming. Ticagrelor is generally prescribed after procedures like angioplasty
or stent placement.
Market Dynamics:
The growth of the ticagrelor market is primarily driven by the increasing
incidence of coronary artery disease globally. As per the World Health
Organization, cardiovascular diseases account for over 17 million deaths
annually, with coronary heart disease being the most common type. Moreover,
rising geriatric population who are more susceptible to heart ailments is also
contributing to the growth of the antiplatelet drug market. The market is also
witnessing significant opportunities in emerging nations due to growing cases
of cardiovascular disorders attributed to rapidly changing lifestyles and
rising obesity rates. However, stringent regulations pertaining to drug
approvals may hamper market growth during the forecast period.
Market key trends:
The ticagrelor market has been witnessing rising geriatric population globally
which is increasing the risk of heart diseases thereby fuelling the market
growth. According to the UN report, the number of people aged 65 years and
above is expected to more than double by 2050 and outnumber children under 15
for the first time in history. Ticagrelor is an important antiplatelet drug
used for treatment of acute coronary syndrome and prevention of
atherothrombotic events in high-risk patients. Thus, growing aging population boosts
the demand for ticagrelor. Another key trend is rising healthcare expenditure
worldwide which is contributing to increased adoption of new drugs like
ticagrelor for treatment of cardiovascular diseases. Additionally, growing
burden of lifestyle diseases caused by changing dietary patterns and lack of
physical activity are also propelling market growth.
SWOT Analysis:
Strength: Ticagrelor has strong efficacy and safety profile for treatment of
acute coronary syndrome. It has demonstrated significant reduction in risk of
myocardial infarction, stroke or cardiovascular death.
Weakness: Being a relatively new drug, its long term safety is not well
established yet. It also has some side effects like bleeding risk which limits
its usage.
Opportunity: Emerging markets offer huge untapped growth potential for
ticagrelor market players. There is also scope for developing novel drug
delivery systems to enhance patient compliance.
Threats: Patent expiry of ticagrelor in coming years can increase competition
from generic drug makers. Stringent regulatory norms also poses challenges for
market players.
Key Takeaways
The Global
Ticagrelor Market Size is expected to witness high growth, exhibiting CAGR of 12.3% over the forecast period
of 2023-2030, due to rising
prevalence of cardiovascular diseases. The market was valued at US$ 1,145.0 million in 2017.
Regional analysis: North America is currently the largest ticagrelor market,
owing to increasing healthcare spending and rising patient awareness about new
effective treatments. Asia Pacific region is expected to grow at fastest pace
during the forecast period due to growing geriatric population, improving
access to healthcare in developing countries, and presence of many key generic
drug players.
Key players: Key players operating in the ticagrelor market are C.H. Boehringer
Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc,
Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories
Pvt. Ltd., and Sun Pharmaceutical Industries Ltd. Few players also pursue
partnerships for advancing their product portfolios. For instance, Natco Pharma
entered into agreement with Pfizer for manufacture and sale of ticagrelor in
India.
Read More - https://www.insightprobing.com/ticagrelor-market-analysis-share-size-and-demand-forecast/
Comments
Post a Comment